$capr

Capricor Therapeutics' Deramiocel shows promising results in Phase [--] trials for Duchenne patients, gaining FDA Fast Track designation. However, the stock faces scrutiny from short sellers, leading to market volatility.

About $capr

Capricor Therapeutics is a biotechnology company focused on developing treatments for rare diseases, particularly Duchenne muscular dystrophy.

Engagements: [-----] (24h)

Engagements 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [------]
[--] Week: [------] +74,810%
[--] Month: [-------] -66%
[--] Months: [---------] +230%
[--] Year: [----------] +178%
1-Year High: [---------] on 2025-12-03
1-Year Low: [---] on 2025-09-20

Engagements by network (24h): X: [-----] YouTube: [--] Reddit: [--]

Mentions: [---] (24h)

Mentions 24-Hour Time-Series Raw Data
Current Value: [---]
Daily Average: [---]
[--] Months: [---] +45,900%
1-Year High: [-----] on 2025-12-04
1-Year Low: [--] on 2025-04-12

Mentions by network (24h): X: [---] YouTube: [--] Reddit: [--]

Creators: [--] (24h)

Creators 24-Hour Time-Series Raw Data
[--] unique social accounts have posts mentioning $capr in the last [--] hours which is down 47% from [---] in the previous [--] hours Daily Average: [---]
[--] Months: [---] +25,100%
1-Year High: [-----] on 2025-12-04
1-Year Low: [--] on 2025-10-24

The most influential creators that mention $capr in the last [--] hours

Creator	Rank	Followers	Posts	Engagements
@TradesProfits	[--]	[---]	[--]	[---]
@Pro_Trader0000	[--]	[--]	[--]	[---]
@RNAiAnalyst	[--]	[------]	[--]	[---]
@anthonystaj	[--]	[-----]	[--]	[---]
@Nkujob	[--]	[---]	[--]	[---]
@TaniaCitradena	[--]	[---]	[--]	[--]
@RamMehar57	[--]	[---]	[--]	[--]
@oliviatrading_6	[--]	[---]	[--]	[--]
@Jamce1182025	[--]	[--]	[--]	[--]
@bronxb_13	[--]	[--]	[--]	[--]

View More

Sentiment: 50%

Sentiment 24-Hour Time-Series Raw Data
Current Value: 50%
Daily Average: 80%
[--] Week: 40% -60%
[--] Month: 38% -31%
[--] Months: 38% -53%
[--] Year: 38% -62%
1-Year High: 100% on 2025-02-18
1-Year Low: 17% on 2025-09-24

Most Supportive Themes:

• Positive Clinical Trial Results: (60%) Capricor Therapeutics announced positive topline results from its Phase [--] HOPE-3 clinical study for Deramiocel, showing significant improvements in skeletal muscle and cardiac function for Duchenne patients.
• FDA Fast Track Designation: (20%) The FDA has granted a Fast Track designation for Deramiocel, indicating a potential for accelerated regulatory review and approval.
• Partnership with Nippon Shinyaku: (15%) The existing partnership with Nippon Shinyaku, which holds rights to Deramiocel in certain regions, is highlighted as a valuable asset.

Most Critical Themes:

• Short Seller Scrutiny and Short Squeeze: (70%) Prominent short sellers, including Martin Shkreli, have been vocal about their bearish stance on CAPR, with some facing significant losses due to a short squeeze.
• Market Volatility and Biotech Sector Risks: (20%) The biotech sector is inherently volatile, and concerns about overall market conditions and potential price corrections are present.

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing